Dear Colleagues, Dear Friends, Dear Everyone,

Gortec has experienced and continues to maintain a strong momentum in its clinical trials over the past few years, some of which are unique, others innovative, and some strategic.
The NIVO-POSTOP study will change practices, with communications planned for 2025.
The biannual meetings of the ENT intergroup provide opportunities to share progress and discuss new projects, with representation from the professions involved in the management of head and neck carcinomas. The group of physicists has regained its rightful place, and the initial work has borne fruit.
The board of directors, whose members are listed just after this message, maintains a strong dynamic and meets at least four times a year:

• President: Yoann Pointreau
• President Elect: Yungan Tao
• Vice President: Christophe Le Tourneau
• Treasurer: Julian Biau
• Vice Treasurer: Xu Shan Sun
• Secretary: Juliette Thariat
• Vice Secretary: Pierre Blanchard
• Along with Pierre Boisselier, Florence Huguet, Anouchka Modesto, and Esma Saada.

Gortec encompasses all the internalized poles to conduct our trials, with some of them incubated within the Early Asset Board chaired by Esma Saada.
The Young Gortec, under the aegis of Yasmine El Houat, continues its deployment.

We always count on all investigators and all centers to effectively include participants in all our trials.
A big thank you to everyone.
See you soon !